Author:
Seidl Christof,Senekowitsch-Schmidtke Reingard
Publisher
Springer Berlin Heidelberg
Reference62 articles.
1. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, LoBuglio AF, Meredith RF (1997) Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65:94–101
2. Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, Horvath G (2001) Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res 21:409–412
3. Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R (2009) Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab’)2—a phase I study. J Nucl Med 50:1153–1160
4. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A (2005a) Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 77:6288–6291
5. Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A (2005b) Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot 62:383–387